Healios

Basic Information

Stock Code
4593
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
February 2011
Listing Year
June 2015
Official Website
https://www.healios.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartseed, AnGes, Nexel Pharma, PeptiDream, SanBio, RenaScience, Qolplus, Takara Bio, ReproCELL, Japan Tissue Engineering, CellSeed

Overview

Healios is a Tokyo-based pharmaceutical company established in 2011, specializing in bio drug discovery using iPS cell-related technologies and advancing the development of innovative pharmaceuticals.

Current Situation

Healios specializes in pharmaceutical development using iPS cell technology, enhancing its competitiveness in the regenerative medicine field. Recent performance has been stable, with active efforts in developing treatments for intractable diseases such as cerebral infarction. It is promoting partnerships with domestic and international research institutions and companies to strengthen its foundational technologies. Emphasizing sustainability, it advances ethical use of cell technologies and focuses on activities fulfilling social responsibilities. In the future, it aims to improve drug discovery efficiency through integration with AI technologies and accelerate practical application in medical settings. It attracts high attention in the industry as a new entrant in bio drug discovery. While differentiating from competitors, it seeks sustainable growth through fundraising and talent development. It continues R&D investments and is preparing for commercialization of products expected for clinical application in the late 2020s. Looking ahead, it has overseas markets in view and is exploring global expansion.

Trivia

Interesting Facts

  • Healios is one of the few companies focusing on pharmaceutical development centered on iPS cell technology.
  • Utilizing AI large language models for cerebral infarction treatment drug development to advance cutting-edge research.
  • Promoting technological innovation through collaborations with multiple universities and research institutions domestically and internationally.
  • Actively acquiring iPS cell-related patents to strengthen technology rights.
  • Engaging in industry proposals for standardization in regenerative medicine.
  • Established integrated service provision from drug discovery to manufacturing support.
  • Also operating cell bank business to provide high-quality cell materials.
  • Focusing on medical education by operating specialized training programs.
  • Integrating AI and big data analysis technologies into new drug development.
  • Leader in the industry for ethical and sustainable bio technology advancement.
  • Progressing global expansion through partnerships with overseas bio companies.
  • Dedicated in-house clinical trial team for efficient trial operations.
  • Developing cell therapy drug candidates for diverse disease areas.
  • Based in Tokyo, active as a hub for medical and biotechnology concentration.
  • Strength in regulatory compliance for regenerative medicine.

Hidden Connections

  • iPS cell technology patent settlement expands technology utilization possibilities for other companies.
  • Entered joint development partnership with Nobel Pharma for severe pneumonia treatment drug.
  • Advancing medical technology development using AI through collaboration with Sakura Net.
  • Simultaneously competing and collaborating with competitor SanBio in research areas.
  • Has collaborative relationships with major players in the CRO industry in clinical trial outsourcing.
  • Formed close collaboration network with advanced medical research bases in Tokyo.
  • Conducting new technology talent development through in-house training integrating AI and bio technologies.
  • Strengthened licensing management capabilities for multiple iPS cell-related technologies following patent settlement.

Future Outlook

Growth Drivers

  • Increased pharmaceutical demand from expanded practical application of iPS cell technology
  • Improved drug discovery efficiency through advanced integration of AI and bio technologies
  • Promotion of clinical applications and legal framework development in regenerative medicine
  • Technology strengthening through expansion of domestic and international partnerships
  • Increased demand for chronic disease treatments amid aging society
  • Expanding needs for clinical trial support services
  • Rising bio pharmaceutical demand in emerging markets
  • Growth in cell bank services and related businesses
  • Increasing investments in ethical and sustainable bio ventures
  • Progress in big data utilization in medical field
  • Enhanced support from government regenerative medicine promotion policies
  • Improved market evaluation of high-quality bio products

Strategic Goals

  • Establish commercialization and mass production system for iPS cell-derived regenerative pharmaceuticals
  • Achieve 50% efficiency improvement in drug discovery processes using AI
  • Expand global market sales ratio to over 40%
  • Gain trust through thorough ethical and regulatory compliance
  • Nationwide rollout of medical education and training programs
  • Expansion and standardization of cell bank business
  • Achieve top-class domestic clinical trial outsourcing volume
  • Company-wide introduction of sustainable manufacturing processes
  • Development and diversified sales of multi-domain bio products
  • Become a leading company in bio field talent development

Business Segments

Regenerative Medicine Formulation Development

Overview
Supports development of regenerative medicine therapeutics using iPS cell technology.
Competitiveness
Integration of advanced iPS cell technology and clinical application know-how
Customers
  • University research institutions
  • Medical institutions
  • Pharmaceutical companies
  • Biotech ventures
  • R&D centers
Products
  • iPS cell-derived therapeutics
  • Gene-modified cells
  • Cell culture media
  • Cell preservation reagents
  • Medical culture kits

Clinical Trial Outsourcing Services

Overview
Provides comprehensive outsourcing services for pharmaceutical clinical trials and studies.
Competitiveness
High-quality trial management backed by deep expertise in iPS cell field
Customers
  • Pharmaceutical companies
  • Medical institutions
  • CRO companies
  • Clinical trial facilities
  • Clinical research support organizations
Products
  • Clinical trial management services
  • Patient recruitment support
  • Data management
  • Safety monitoring
  • Clinical trial consulting

Bio Manufacturing Support

Overview
Provides various supplies to support regenerative medicine manufacturing sites.
Competitiveness
Provision of high-quality manufacturing materials meeting medical standards
Customers
  • Biopharma companies
  • Clinical research institutions
  • Medical device manufacturers
  • Research institutes
  • Clinical trial institutions
Products
  • Manufacturing reagents
  • Culture kits
  • Quality control reagents
  • Culture equipment
  • Sterile disposables

AI Drug Discovery Support Solutions

Overview
Supports efficiency improvement in drug discovery research using AI technology.
Competitiveness
Advanced utilization of AI technologies specialized for pharmaceutical development
Customers
  • Pharmaceutical companies
  • Biotech ventures
  • Research institutions
  • Technology companies
Products
  • Drug discovery AI platform
  • Data analysis services
  • Large language models
  • Simulation tools

Pharmaceutical Patent Management and Licensing Support

Overview
Supports intellectual property management and rights utilization for iPS cell-related technologies.
Competitiveness
Specialized IP know-how in the iPS cell field
Customers
  • Pharmaceutical companies
  • Research institutions
  • Venture companies
  • Patent firms
Products
  • Patent search services
  • Licensing contract support
  • Rights management platform

Regenerative Medicine Device Development

Overview
Develops and provides devices for clinical application of regenerative medicine.
Competitiveness
Medical device technology optimized for cell applications
Customers
  • Medical device manufacturers
  • Hospitals
  • R&D institutions
Products
  • Cell culture devices
  • Transplantation instruments
  • Quality management systems

Clinical Trial Data Analysis Services

Overview
Handles analysis and reporting of large-scale data from clinical trials.
Competitiveness
Specialized analysis know-how in regenerative medicine
Customers
  • Pharmaceutical companies
  • Research institutions
  • CROs
Products
  • Clinical data analysis
  • Bioinformatics support

Medical Education and Training Services

Overview
Supports technical education and talent development in regenerative medicine.
Competitiveness
Provision of educational content responsive to on-site needs
Customers
  • Medical institutions
  • Educational institutions
  • Pharmaceutical companies
Products
  • Regenerative medicine training programs
  • Medical technology workshops

Pharmaceutical Approval Support Services

Overview
Provides specialized support for pharmaceutical approval processes.
Competitiveness
Drug affairs know-how detailed for iPS cell-related products
Customers
  • Pharmaceutical companies
  • Biotech ventures
  • Medical institutions
Products
  • Pharmaceutical regulations consulting
  • Application document preparation support

Health Food and Supplement Development

Overview
Supports development of health foods applying regenerative medicine technology.
Competitiveness
Product development capabilities based on scientific evidence
Customers
  • Health food manufacturers
  • Retailers
  • Wholesalers
Products
  • Bio-based supplements
  • Functional food ingredients

Cell Bank Services

Overview
High-quality cell stocks and management services.
Competitiveness
Secure cell supply system
Customers
  • Research institutions
  • Medical institutions
  • Pharmaceutical companies
Products
  • iPS cell stock
  • Cell storage services

Medical Information Platform

Overview
Supports secure sharing and utilization of medical and research data.
Competitiveness
Advanced data management and analysis technologies
Customers
  • Medical institutions
  • Research institutions
  • Pharmaceutical companies
Products
  • Clinical data sharing system
  • Research support tools

Competitive Advantage

Strengths

  • Possession of advanced iPS cell technology
  • Specialized knowledge in regenerative medicine
  • Strong R&D organization
  • Domestic and international partnership network
  • Specialized services for clinical trials
  • Promotion of drug discovery through AI integration
  • Diverse bio product lineup
  • Securing of excellent research talent
  • Establishment of patent rights
  • Ethical and sustainable technology development
  • Specialization in regenerative medicine formulations
  • High-quality manufacturing support technology
  • Cell bank operation track record
  • Comprehensive medical education programs
  • Expertise in clinical trial data analysis

Competitive Advantages

  • Differentiation through top-tier domestic iPS cell application capabilities
  • Strength in bio drug discovery enabling early clinical deployment
  • Proprietary regenerative medicine kits and manufacturing technologies
  • Strong alliances with research institutions and companies
  • Efficiency and cost reduction in drug discovery via AI utilization
  • Talent development and retention system for highly specialized personnel
  • Strong consulting capabilities for pharmaceutical regulations
  • Multi-domain business expansion covering multiple areas
  • Focus on IP management for technology protection
  • Product development responsive to medical site needs
  • Rapid material supply leveraging cell banks
  • Trust gained through consideration of ethical issues
  • Diverse sales channels and customer base
  • Research support capabilities using AI language models
  • Experience in high-quality clinical trial operations

Threats

  • Funding uncertainty due to prolonged drug development
  • Competitors' technological innovations and patent strategies
  • Rising development costs from stricter regulations
  • Risks in addressing ethical issues with iPS cell technology
  • Business uncertainty from market demand fluctuations
  • Intensified competition from increasing new entrants
  • Uncertainty risks in clinical trial results
  • Overseas expansion restrictions due to international political changes
  • Potential risks of IP infringement or patent disputes
  • Manufacturing delays from material supply issues
  • Risk of research talent outflow
  • Decline in competitiveness from technology obsolescence

Innovations

2024: Utilizing AI Language Model for Cerebral Infarction Treatment

Overview
Collaborating with Sakura Net to conduct verification of new treatment methods using large language models.
Impact
Contributes to improved treatment efficacy and drug discovery efficiency

2023: Strengthening Regenerative Medicine Drug Development Using iPS Cell Technology

Overview
Initiated clinical trials for neurological disease therapeutics, advancing technology development and practical application.
Impact
Significant progress toward product commercialization

2022: Introduction of AI and Data Analysis Platform

Overview
Developed and introduced drug discovery AI platform, improving speed and accuracy of drug discovery processes.
Impact
Reduced new drug candidate selection time by 40%

2021: Initiation of iPS Cell-Derived Cardiomyocyte Therapeutics Development

Overview
Began research on new cell therapeutics for myocardial infarction treatment.
Impact
Contributes to expansion of treatment options

2020: New Development of Regenerative Medicine Culture Media

Overview
Developed culture media aimed at improving cell culture efficiency and stabilizing quality.
Impact
Improved culture efficiency by 10%

Sustainability

  • Promotion of ethical cell technology use
  • Enhanced safety management in regenerative medicine
  • Improvement of manufacturing processes to reduce environmental impact
  • Implementation of regional medical contribution programs
  • Promotion of diversity and inclusion